Novo Nordisk A/S announced a workforce reduction of approximately 9,000 employees globally as part of a company-wide transformation aimed at improving efficiency and reallocating resources for growth in diabetes and obesity markets, with a restructuring cost of DKK 8 billion. This change, effective immediately, seeks to achieve annual savings of DKK 8 billion by 2026 while expecting a 4-10% growth in operating profit for 2025.